Report of Foreign Issuer (6-k)

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of: February 2019

Commission File Number: 001-35776

 

 

 

ACASTI PHARMA INC.

(Name of Registrant)

 

 

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office )

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F   x             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ¨

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		ACASTI PHARMA INC.
Date: February 14, 2019	By:	/s/ Jan D'Alvise
		Name: Jan D'Alvise Title: Chief Executive Officer

 

 

 

 

 

 

 

EXHIBIT INDEX

 

 

Exhibit	Description of Exhibit
99.1	Sales Agreement, dated February 14, 2019, between Acasti Pharma Inc. and B. Riley FBR, Inc.
99.2	Opinion of Osler, Hoskin & Harcourt LLP